A doctor at the centre of a review of the treatment of more than 200 patients with lung disease is being investigated by the ...

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...

Survival rates for idiopathic pulmonary fibrosis are worse than all solid cancers except for lung and pancreatic cancer. | ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

More than 200 patients have had their lung disease treatment reviewed following concerns their care at a Surrey hospital did ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Overall, the collective findings from this Phase 1b clinical trial provide the Company with strong confidence that LTI-03 has ...

Sep. 26, 2024 — What factors lead to chronic respiratory disease? Researchers investigated ... respiratory illnesses like asthma and pulmonary fibrosis just got easier if a new drug-carrying ...